Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novel US FDA Approvals Could Rebound In 2017: 40+ Candidates Already Under Review

Executive Summary

Novel approvals by US FDA in 2017 could easily surpass the 28 agents approved by the agency's drug and biologics centers in 2016. The big question is whether last year's spike in complete response letters was an anomaly or the start of a trend.


Related Content

New Active Substance Launches Declined Again In 2016
Pharma's First Quarter: Approvals, Successes and Setbacks
Keeping Track: US FDA Files Another Pfizer Cancer Biologic And TMC's New Antibiotic
US FDA Approval Of Valeant’s Siliq Comes With REMS, Boxed Warning
Time For Big Pharma To Take Back Orphan Drugs
Novel Approvals Were Fewer But Faster At US FDA In 2016
What Goes Up … US FDA Expects 2016 NME Approval Total To Come Down


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts